Knight Therapeutics (TSX:GUD) Additional Paid-In Capital : C$26.7 Mil(As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Additional Paid-In Capital?

Knight Therapeutics's quarterly additional paid-in capital declined from Sep. 2024 (C$26.2 Mil) to Dec. 2024 (C$25.7 Mil) but then increased from Dec. 2024 (C$25.7 Mil) to Mar. 2025 (C$26.7 Mil).

Knight Therapeutics's annual additional paid-in capital increased from Dec. 2022 (C$23.7 Mil) to Dec. 2023 (C$26.0 Mil) but then declined from Dec. 2023 (C$26.0 Mil) to Dec. 2024 (C$25.7 Mil).

Knight Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Knight Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Additional Paid-In Capital Chart

Knight Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

18.73

21.78

23.66

25.99

25.71

Knight Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															26.50	25.66	26.22	25.71	26.72

Knight Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Knight Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Executives

Sime Armoyan	10% Security Holder
Samira Sakhia	Director, Senior Officer
Amal Khouri	Senior Officer
Jonathan Ross Goodman	Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande	Director
Long Zone Holdings Inc.	10% Security Holder
Janice Jean Murray	Director
Nicolas Sujoy	Director
Arvind Utchanah	Senior Officer
Michael Joseph Tremblay	Director
James Gale	Director
Michael Dehn	Director, Senior Officer
Andrew Moor	Senior Officer
Patrick Mcclymont	Senior Officer
Kevin Drew Nabholz	Director

Knight Therapeutics Headlines

No Headlines